Sysmex Inostics, a division of Sysmex Corporation, is an innovative molecular diagnostics firm specializing in the detection of mutations in oncology using advanced technologies such as BEAMing (digital PCR) and SafeSEQ (NGS) to analyze cell-free tumor DNA (ctDNA) in the bloodstream. These cutting-edge methods were originally pioneered by specialists at the Johns Hopkins School of Medicine more than ten years ago, and this extensive expertise in ctDNA analysis forms the foundation of Sysmex Inostics' technology development and implementation capabilities. With over a decade of expertise in liquid biopsy, Sysmex Inostics continues to lead the way in this field.